Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug ...

Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
MarketBeat on MSN

Annexon highlights Q4 geographic atrophy data, GBS filing plans at BofA conference

Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...
Nasdaq

Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway

Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Healio

Alternative complement pathway inhibition may be key to lupus management

Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Ophthalmology Times

Biogen completes acquisition of Apellis Pharmaceuticals

Biogen’s Apellis acquisition consolidates a complement franchise spanning retinal and renal indications, with near-term label ...